Pulmonx Statistics
Total Valuation
Pulmonx has a market cap or net worth of $53.64 million. The enterprise value is $48.36 million.
Important Dates
The last earnings date was Wednesday, April 29, 2026, after market close.
| Earnings Date | Apr 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pulmonx has 42.24 million shares outstanding. The number of shares has increased by 4.39% in one year.
| Current Share Class | 42.24M |
| Shares Outstanding | 42.24M |
| Shares Change (YoY) | +4.39% |
| Shares Change (QoQ) | +1.19% |
| Owned by Insiders (%) | 5.16% |
| Owned by Institutions (%) | 74.29% |
| Float | 37.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.61 |
| Forward PS | 0.56 |
| PB Ratio | 1.17 |
| P/TBV Ratio | 1.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.91, with a Debt / Equity ratio of 1.23.
| Current Ratio | 4.91 |
| Quick Ratio | 3.85 |
| Debt / Equity | 1.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.54 |
Financial Efficiency
Return on equity (ROE) is -86.22% and return on invested capital (ROIC) is -27.49%.
| Return on Equity (ROE) | -86.22% |
| Return on Assets (ROA) | -24.04% |
| Return on Invested Capital (ROIC) | -27.49% |
| Return on Capital Employed (ROCE) | -51.51% |
| Weighted Average Cost of Capital (WACC) | 4.84% |
| Revenue Per Employee | $299,139 |
| Profits Per Employee | -$179,760 |
| Employee Count | 296 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 1.31 |
Taxes
In the past 12 months, Pulmonx has paid $640,000 in taxes.
| Income Tax | 640,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -64.25% in the last 52 weeks. The beta is 0.13, so Pulmonx's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | -64.25% |
| 50-Day Moving Average | 1.43 |
| 200-Day Moving Average | 1.74 |
| Relative Strength Index (RSI) | 44.62 |
| Average Volume (20 Days) | 478,022 |
Short Selling Information
The latest short interest is 2.81 million, so 6.66% of the outstanding shares have been sold short.
| Short Interest | 2.81M |
| Short Previous Month | 2.86M |
| Short % of Shares Out | 6.66% |
| Short % of Float | 7.53% |
| Short Ratio (days to cover) | 7.04 |
Income Statement
In the last 12 months, Pulmonx had revenue of $88.55 million and -$53.21 million in losses. Loss per share was -$1.29.
| Revenue | 88.55M |
| Gross Profit | 66.84M |
| Operating Income | -52.06M |
| Pretax Income | -52.57M |
| Net Income | -53.21M |
| EBITDA | -51.16M |
| EBIT | -52.06M |
| Loss Per Share | -$1.29 |
Full Income StatementBalance Sheet
The company has $61.57 million in cash and $56.29 million in debt, with a net cash position of $5.28 million or $0.12 per share.
| Cash & Cash Equivalents | 61.57M |
| Total Debt | 56.29M |
| Net Cash | 5.28M |
| Net Cash Per Share | $0.12 |
| Equity (Book Value) | 45.76M |
| Book Value Per Share | 1.08 |
| Working Capital | 73.84M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$29.25 million and capital expenditures -$160,000, giving a free cash flow of -$29.41 million.
| Operating Cash Flow | -29.25M |
| Capital Expenditures | -160,000 |
| Depreciation & Amortization | 896,000 |
| Net Borrowing | 1.69M |
| Free Cash Flow | -29.41M |
| FCF Per Share | -$0.70 |
Full Cash Flow StatementMargins
Gross margin is 75.49%, with operating and profit margins of -58.79% and -60.09%.
| Gross Margin | 75.49% |
| Operating Margin | -58.79% |
| Pretax Margin | -59.37% |
| Profit Margin | -60.09% |
| EBITDA Margin | -57.78% |
| EBIT Margin | -58.79% |
| FCF Margin | n/a |
Dividends & Yields
Pulmonx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.39% |
| Shareholder Yield | -4.39% |
| Earnings Yield | -99.19% |
| FCF Yield | -54.83% |
Analyst Forecast
The average price target for Pulmonx is $5.38, which is 323.62% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.38 |
| Price Target Difference | 323.62% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 32.90% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pulmonx has an Altman Z-Score of -5.42 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.42 |
| Piotroski F-Score | 3 |
